Engine Biosciences raises $43M for combo genetic platform

By The Science Advisory Board staff writers

May 26, 2021 -- Engine Biosciences has raised $43 million to advance its drug discovery and development platform, which uses next-generation combinatorial genetics to decipher genetic codes. The company will use the funds to expand its portfolio of precision oncology therapeutics, prepare for its first clinical programs, and scale its proprietary technology platform.

Engine's platform allows researchers to uncover the gene interactions and biological networks underlying diseases to generate insights for precision medicine applications, according to the firm.

Engine's foundational technologies include NetMAPPR, a searchable biology platform that finds gene combinations and drug targets integral to diseases, and combinatorial genetics en masse (CombiGEM), which uses combinatorial CRISPR technology to enable experimental confirmation of how genes and gene combinations relate to disease.

Initially, Engine will focus on oncology applications by developing targeted therapies for genetically defined patient populations in treating liver, ovarian, colorectal, and breast cancers.

The oversubscribed series A funding was led by Polaris Partners.


Copyright © 2021 scienceboard.net


Conferences
CPhI North America
August 10-12
Philadelphia, Pennsylvania United States
Bioprocessing Summit
August 16-19
Boston, Massachusetts United States
6th Annual CAR-TCR Summit
August 30 - September 2
Online
European Congress of Immunology (ECI) 2021
September 1-4
Belgrade Serbia
Medical Affairs Strategic Summit (MASS)
September 13-15
New Brunswick, New Jersey United States
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter